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Section III : 
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Section I : GWAS and inflammatory marker genetics
In the first section of this thesis I focused on elucidating the genetic basis for a set 
of clinically relevant inflammatory markers. Following developments in DNA chip 
genotyping, both upscaling and miniaturisation, the analysis of many genetic variants in 
one experiment in a feasible timeframe and for reasonable costs became possible and 
resulted in the first GWAS experiments1,2. 
For inflammatory markers, the first GWAS was performed in 2007 for C-Reactive Protein 
(CRP), Interleukin 6 (IL6), and Tumor Necrosis Factor (TNF) as part of a systematic GWAS 
on biomarkers measured in up to 1008 individuals, where only for CRP one genome-
wide significant association was identified3. In later years, the power to detect additional 
loci improved, by ever-increasing sample sizes and improved granularity by means of 
imputation to reference panels, resulting in the identification of additional loci for each 
trait, but still leaving a large part of the heritability for these traits unexplained. When 
assessing prior GWAS work up to now, several important general observations are 
evident: 
I) Firstly the GWAS paradigm is a powerful approach to identify genetic variation 
underlying complex traits; a brief glance at the GWAS catalog4 shows that from 2009, 
the number of SNPs found associated with complex traits ran into the 1000s, previously 
considered impossible through either candidate gene association or linkage studies. 
II) Secondly, the common disease – common variants hypothesis appeared to be correct; 
for many diseases and traits it appears that many different genetic common variants 
throughout the genome contribute to the architecture of complex traits, albeit with small 
effects.
III) Even though many genetic loci have been identified with small effects a large portion 
of the heritability remains unexplained for the majority of traits.
IV) Genetic variants involved in certain traits can be population specific, and pinpointing 
causal variants remains difficult.
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V) Lastly, stringent quality control for GWAS results is essential to avoid false positives.
Learning from these observations, it is to this end, that in section I of this thesis I aimed 
to further elucidate the genetic background of some of the clinically most relevant 
inflammatory biomarkers, namely IL6, TNF, total protein and albumin, by substantially 
increasing sample sizes, in some cases including data from different populations and 
narrowing down genomic locations containing causal variants, all supported by the 
development of a standardised GWAS quality control pipeline.
The need for high-quality GWAS results and high-throughput QC
In Chapter 2, we first present a software suite that enables automated quality control 
for GWAS summary statistics5. The output from GWAS typically is a plain text file, having 
several columns containing summary statistics, such as p-values and effect sizes and 
information about the genomic location and quality of a variant. When contributing GWAS 
results to a meta-analysis consortium, the summary statistic files generated by analysis 
programs are normally first pre-processed with custom-written scripts so as to meet 
the standard format outlined by the relevant GWAS consortium and as required by meta-
analysis software. As in a typical GWAS 2.5 to 3 million variants are analysed, the resulting 
files are several millions of lines in length and multiple columns in width, which does not 
allow manual checking, especially since one sometimes has to deal with hundreds of files 
for a consortium. However, failing to perform quality control can have various negative 
consequences, from files being non-processable, to identifying false-positive hits and 
publishing these6. We therefore developed an R-package that could automatically process 
GWAS result files, visualizing various quality parameters at once, and simultaneously 
formatting the output results in a desired format. At the time of development, to our 
knowledge only one other pipeline had been developed to semi-automatically check 
GWAS results, albeit with several crucial drawbacks, the most important being the 
lack of: cross-study comparable QC log file generation, the ability to generate clean 
standardised GWAS output files, the automatic serial throughput of files without writing 
custom scripts, and the harmonisation of variant definitions using a reference panel of 
SNPs, all of which are currently implemented in our QCGWAS R-package. This package 
has been used to perform the QC for the GWAS results in Chapters 3 to 5 and has saved 
considerable time and efforts. 
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Nevertheless, there remains room for improvement. Firstly, since imputation reference 
panels become increasingly large, the time to process result files, as well as memory 
requirements increase accordingly. Whereas Hapmap-based result files as in Chapters 
3 to 5 typically contain 2.5 to 3 million variants, taking between 5 and 15 minutes per 
file on an ordinary desktop PC, with a memory usage between 2 and 3 GB, more recent 
imputation panels such as the 1000 Genomes reference based data with over 10 million 
variants, take over 40 minutes and 20 GB of RAM, far too much when having to process 
hundreds of files. Improvements on processing speed can be sought in multiple ways ; by 
for example writing parts of the pipeline in lower-level programming languages such as 
C++, which can speed up certain computations several hundred fold7. Additionally, when 
keeping R architecture, various packages have been developed to scale-up R capabilities 
to handle ‘big data’, by giving R parallel computing capabilities8, and resolving it’s memory 
devouring habits, such as the ff and bigmemory packages9,10 that cleverly make use of the 
hard disk as memory space and memory-mapping tools. A second major improvement 
for QCGWAS could be the automatic checking of GWAS results against known positive 
controls for a certain trait. Now that many thousands of variants are identified for 
hundreds of traits, positive controls can be easily (and automatically) retrieved from 
the GWAS catalog, enabling effect-size consistency checks for individual GWAS results, 
allowing the identification of a multitude of problems, such as whether the correct trait 
was analysed, or whether perhaps sample mix-ups have occurred and so on. A third and 
last idea for improvement can be the variant strand alignment checking to a reference 
for ambiguous SNPs. Currently, ambiguous SNPs whose allele-frequency differ strongly 
from that of the reference are marked as suspect (i.e. not properly aligning, in QCGWAS 
defined as < 0.35. versus > 0.65 allele frequency difference compared to the reference), 
though the frequency of variants can obviously differ between studies and populations, 
and proper alignment by looking at frequencies is very hard to determine if the minor allele 
frequency is nearing 50%. Instead, use can be made of linkage disequilibrium patterns in 
the reference data. Proper strand assignment for ambiguous SNPs can potentially be 
achieved by comparison of these to frequencies of nearby non-ambiguous SNPs that are 
in very high LD with the ambiguous SNP, that tend to have very similar allele frequencies. 
Biological insights from large-scale meta-GWAS analyses for 3 major inflammatory markers
In Chapters 3 to 5 we performed the largest-ever meta-analyses for four major 
biomarkers associated with inflammation, being TNF, and IL6, total protein and albumin 
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concentrations. The last two are used for various clinical purposes.
For TNF, we were the first to identify reliable genomic loci, 3 in total, associated with 
its circulating levels in blood. This is a classic example of the merits of pooling GWAS 
results so as to increase statistical power to detect loci. Our 3 loci for TNF provide 
interesting biological insights. Reassuringly, we, for example, showed that two of our loci 
harbour genes for cytokines and regulators of cytokines (6p21 / LTA and 12q24 / SH2B3). 
Interestingly, our third locus provided evidence for involvement in lipid metabolism (15q21 
/ LIPC).  It has been long known that TNF is a very potent lipid metabolism regulator, 
but our study for the first time pinpoints a genetic locus that may provide a link to this 
involvement. 
Similarly, for IL6 we were able to report 3 loci, two of which were novel. Up to now, only 
the well-established IL6R locus has been known for its involvement in determining IL6 
levels in blood, which is a highly pleiotropic locus harbouring variants influencing various 
traits including CRP, and fibrinogen, but also diseases such as Coronary Artery Disease 
(CAD), Rheumatoid Arthritis (RA) and asthma. The two novel loci, 2q14 and 6p21 harbour 
well-known inflammation related genes, (IL1F10 and IL1RN for 2q14 and HLA-DRB1/
DRB5 for 6p21. 
In the meta-analysis of serum-albumin and total protein concentration, we identified six 
loci for serum albumin that harbour genes related to ribosome function (19q13 / HPN-
SCN1B, 2p23 / GCKR-FNDC4, 17p13 / SERPINF2-WDR81, 18q21 / TNFRSF11A-ZCCHC2, 
15q15 / FRMD5-WDR76, and 19q13 RPS11-FCGRT), and 3 loci associated with serum 
total protein (17p11 / TNFRS13B, 6q21.3, and 5q15 / ELL2), harbouring genes related 
to immune function11. In this case, we demonstrated that lead SNPs at the identified 
loci have themselves been reported or are in moderate to high LD (r2 > 0.5) with those 
reported in the GWAS catalogue for a very diverse range of human complex traits, and 
reassuringly, are enriched for metabolic phenotypes that are associated with, or are 
direct products of, protein metabolism. 
Fine-mapping
The majority of GWAS lead SNPs are intergenic, and even in the case they do reside within 
a gene, their functional impact remains difficult to assess when not directly affecting 
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protein-coding (i.e. being intronic). In addition, pin-pointing the variants within a locus that 
make an actual causal contribution to the trait of interest remains challenging, as it is not 
necessarily the top-signal within a locus that might be causally contributing. Therefore, in 
Chapter 5, we applied two subsequent methods to substantially improve fine-mapping of 
genomic loci involved in determining serum levels of total protein and albumin11. First, we 
applied a novel GWAS meta-analysis method, MANTRA, that facilitates further narrowing 
down a genomic region containing actual causal variants. It allows for heterogeneity in 
allelic effects between ancestry groups using a Bayesian approach. This method capitalises 
on the varying LD structures between populations of different ancestry, which enabled us 
to define narrower regions of association. Secondly, we defined ‘‘credible sets’’ of SNPs, 
contained in a genomic window that with 99.9% probability contains the causal variants, 
which are those variants with the strongest signals of association and, hence, most likely 
to be causal (or tagging an unobserved causal variant). In total, we identified nine novel 
loci associated with the traits investigated. We observed improved resolution, in terms 
of the number of SNPs and the genomic interval covered by the credible set for various 
loci for both traits. The most striking improvements in resolution were observed at the 
6q21.3 locus for total protein, wherein the 99% credible set was reduced from 14 SNPs 
(covering 346 kB), to just three (covering 37 kB). Furthermore, after trans-ethnic meta-
analysis, the posterior probability that the lead SNP was causal (or tagged an unobserved 
causal variant) was more than 95% at 2p23 / GCKR-FNDC4 and 17p13 / SERPINF2-WDR81 
for serum albumin and at 17p11 / TNFRS13B and the 6q21.3 locus for total protein. Given 
the results of these efforts, fine-mapping using a combination of methods should be a 
standard component of each (meta-) GWAS analysis.
Functional impact 
Traditionally, lead variants are typically annotated using databases such as ANNOVAR12 
as done in Chapters 3 to 5, to obtain initial biological insights as whether these are 
protein coding or not and if so whether nucleotide substitutions result in amino-acids 
changes that have functional consequences. One way to assess functional impact of 
variants on a phenotypic level is to correlate the genotypes of lead variants with the 
mRNA expression of nearby genes, referred to as (cis-) expression quantitative trait locus 
(eQTL) mapping. In Chapter 5, we mapped lead SNPs at four of the identified loci to cis 
expression levels of 18 genes, for which one of the strongest associations was observed 
for expression of HLA- DQA1/2, which is a human leukocyte antigen (HLA) class II antigen 
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with an immune system role related to processing and presentation of antigen peptides. 
Even though this way initial clues about functional impact of variants can be elucidated, 
higher-order effects on protein and phenotypical levels cannot be resolved. Instead, a 
direct way to test effects of variants or genes they reside in can be done through the 
use of model animals such as zebrafish or mice. For example, in Chapter 5 we identified 
an association in the 19q13 / HPN-SCN1B locus, at which the lead SNP is an intronic 
SNP within HPN, a gene encoding hepsin. Hepsin is a membrane-bound serine protease 
with substrate specificity for basic amino acids similar to those involved in proalbumin 
processing, which suggests a physiologic role of hepsin in the cleavage of proalbumin to 
albumin. By knocking out hepsin in a mouse model, and comparing serum protein and 
albumin concentrations between these knockout mice and wild-type litter mates, we 
found overwhelming evidence of reduced serum albumin and, to a lesser extent, reduced 
total protein, showing that the use of animal models can be a valuable tool to provide 
functional evidence supporting GWAS findings. 
Section II : Integrative post-GWAS analyses and aetiological involvement
Having identified and fine-mapped genetic associations is the first step towards 
understanding the molecular basis of traits. In order to understand how a phenotype is 
established through changes in DNA sequence, the functional impact of variants must 
first be understood, both individually, but also in combination on a systemic level, as I 
have pursued in Section II of this thesis. 
Systems genetics
Even when we have established functional consequences on mRNA and protein levels, 
the exact molecular mechanisms through which variants and the genomic loci they 
reside in exert their effects on the phenotype cannot be resolved by evaluating these 
individually. Instead, clues about how these act in concert can be gathered using 
various approaches, collectively known as systems genetics. In Chapter 5, we used two 
complementary approaches: we performed a pathway analysis using MAGENTA13, which 
is a method that evaluates the enrichment of sets of genes harbouring our meta-analysis 
variants that belong to pre-defined biological pathways. Amongst identified pathways 
we identified RNA processing and protein-trafficking-related pathways. Secondly, one 
can also look at how the proteins encoded by genes mapping to our loci interact. Proteins 
that heavily interact are likely to belong to a confined part of a molecular pathway and 
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/ or physiological process. Using programs such as Cytoscape14, that can model such 
interactions, together with clustering algorithms and pathway annotation, we identified 
several clusters of strongly interacting proteins. These clusters were enriched for 
ribosomal functioning and protein translation, proteasomal protein degradation, and 
immune response signalling. Both the pathway analysis and protein-interaction analyses 
identified molecular processes that were most relevant to the investigated phenotypes. 
On the basis of the functional analysis approaches taken in Chapter 5, collectively referred 
to as ‘post-GWAS’ analyses, and following suggestions in Chapter 815, we developed 
a standardised pipeline in Chapter 6 that integrates a number of in-silico functional 
approaches16. In brief, in Chapter 6 we first performed ‘in silico’ sequencing, exploring the 
vicinity of GWAS SNPs to identify all linked variants. In the second phase, we performed 
eQTL analyses, where we attempted to identify all nearby genes whose expression 
levels are associated with the corresponding GWAS SNPs. These two phases generated 
a number of relevant genes that served as input to the next phase of functional network 
analysis using GeneMANIA17,18 and Cytoscape14. The application of this pipeline to loci 
identified in the at that time largest ever meta-GWAS analysis done for CRP, yielded a 
range of enriched biological processes such as the acute-phase response or the acute 
inflammatory response. About one third of the significantly enriched terms were related 
to immunologic processes, cytokines, and interferons. Interestingly, the majority of the 
identified processes pointed to an involvement of interferon biology, in particular, type I 
interferon associated biological processes, of which the connection to CRP was previously 
not widely recognised.
Clinical relevance and causal involvement
In Chapters 3 to 5 we identified genomic loci or in some cases specific variants for the various 
biomarkers that affect a wide range of diseases, including common cardiovascular traits 
and diseases such as coronary heart disease and diastolic and systolic blood pressure, 
but also auto-immune diseases such as rheumatoid arthritis, type 1 diabetes and celiac 
disease. In other words, these loci appear to be pleiotropic. However, identifying genetic 
overlap between biomarkers and disease does not necessarily imply causal involvement, 
even though various biomarkers investigated in this thesis are correlated with disease 
status, used in clinical practice to evaluate disease progression and prognosis, or in the 
case of TNF and IL6, even used as direct targets of intervention.
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Amongst the biomarkers investigated in this thesis, CRP has long been suspected to be 
causally involved in a number of diseases. Epidemiological studies have shown that CRP 
is associated with and exhibited a reliable predictive value for cardiovascular disease19,20, 
type 2 diabetes21, and immunity-related disorders such as inflammatory bowel disease 
(IBD)22, rheumatoid arthritis23 and all-cause mortality24. Nevertheless, the evidence for 
a causal involvement of CRP from traditional experimental or observational studies 
remains controversial. Causal involvement can however be evaluated by means of an 
approach known as Mendelian randomization (MR). These types of analyses make use of 
genetically informed instrumental variables (IVs), that is, sets of genetic variants known 
to have an effect on the exposure of interest, to actually model c.q. genetically reflect this 
exposure, in this case CRP levels. 
In Chapter 7 we selected a panel of 32 different traits and diseases in five broad classes, 
(i.e. auto-immune-inflammatory, cardiovascular, metabolic, neuro-degenerative and 
psychiatric), for which association with elevated CRP levels in epidemiological studies has 
been observed, and performed MR analyses genetically  modelling levels of CRP to test 
causal effects of these on the selected traits. For our MR analyses, we constructed two 
genetic IV’s, one using four SNPs representing only the CRP gene, to avoid any pleiotropic 
effects  - one of the assumptions necessary for performing MR, and another IV using up to 
18 SNPs that were associated with CRP levels at genome-wide significance in the largest 
GWAS for CRP to date. We identified a significant causal protective association of CRP 
and schizophrenia, and nominal, yet to be confirmed, evidence for a causal involvement 
in psoriatic osteoarthritis, rheumatoid arthritis, knee osteoarthritis, SBP, DBP, serum 
albumin levels, and bipolar disorder. We could however not demonstrate any causal 
effect of CRP on other common somatic and neuropsychiatric outcomes investigated in 
this study. The apparent non-causal involvement of CRP in the other sets of traits also 
means that drug interventions targeting CRP for these traits will unlikely be of benefit. 
An important aspect of this study was not only the identification of the causal association 
between CRP and schizophrenia, but the mere fact that individual-level genotype data 
was not required for the analyses, and instead we could make use of publicly available 
GWAS summary statistics, which contributed substantially to the feasibility of this study. 
Nevertheless, these types of MR approaches have to be carefully applied. MR analyses 
require several assumptions, the violation of which can introduce severe bias. One of 
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the most precarious is that the instruments need to be “pleiotropy-free”, i.e., the genetic 
instruments used in the MR analysis may not be associated with any unmeasured 
phenotype that is related to the outcome of interest. We identified several genes being 
pleiotropic through assessing heterogeneity of effects of variants, some of which with 
well-known pleiotropic effects, such as GCKR (mapped in our study by rs1260326), 
absence of heterogeneity of effects does not automatically imply absence of pleiotropy. 
Though absence of pleiotropy is rather difficult to be proven empirically, there are several 
additional tests that can be utilised to try to falsify assumptions about pleiotropy and thus 
to minimize the chance of bias25, such as using multiple different instrumental variables 
for different genes and showing consistent results for the MR analyses with these.
FUTURE PERSPECTIVES
In the first section of this thesis I focused on the discovery of new genetic loci for various 
inflammatory biomarkers. Even though for each of these markers we substantially 
increased the number of loci involved in these traits, we still are only able to explain just a 
fraction of the estimated heritability. As a direct consequence this also limits the capability 
to provide (causal) functional insights in mechanisms through which genetic variants 
exert their effects on the phenotype of interest. I will therefore firstly provide some views 
on how genetic discovery of novel loci can be improved and further extended, followed 
by a discussion of how recent advances in functional genomics will aid understanding of 
the link between genotype and phenotype as was aimed for in Section II of this thesis . 
9.1. Overcoming the limitations of genetic loci discovery 
9.1.1. Increase in power
Super-consortia
As mentioned earlier, one of the simplest ways to uncover substantially larger parts 
of the so-called ‘missing heritability’ is by simply increasing sample size, which in turn 
increases statistical power. From very early on, this has been done through combining 
GWAS results of individual studies in large meta-analyses, facilitated by the formation 
of large GWAS consortia, which are often phenotype-specific. Well-known examples 
are the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC)26 and 
DIAbetes Genetics Replication And Meta-analysis (DIAGRAM)27 consortia that focus on 
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type 2 diabetes and related traits, the Coronary ARtery DIsease Genome wide Replication 
And Meta-analysis (CARDIoGRAM) consortium28 that focuses on coronary artery disease. 
The largest consortium to date is the Genetic Investigation of ANthropometric Traits 
consortium (GIANT)29, which focuses on anthropometric traits, of which their first 
publication on height as a model complex trait, including >180,000 samples30, showed 
that their identified genetic loci could approximately explain 10.5% of the explained 
variance for height. A few years later, a larger effort, of >250,000 samples31, was able 
to explain 16%, and estimated that all common variants involved in the phenotype could 
explain as much as 60%. As various consortia arise working on similar phenotypes, these 
typically publish either simultaneously (‘back to back’), or sometimes efforts would scoop 
each other. In more recent years, consortia have realised that sample resources are finite, 
and started to join efforts to further improve sample sizes, such as CARDIoGRAM that 
has teamed up with the Coronary Artery Disease Genetics Consortium (C4D)32. 
Biobanking
Further efforts to increase sample sizes come from various directions. For example, 
the recognition of public bodies of the importance of data-driven healthcare, led to the 
establishment of several biobanks, a well known example being the UK Biobank effort, 
that aims to improve prevention, diagnosis and treatment of illness, and the promotion of 
health through society33. Up to now, roughly 500,000 samples have been collected with 
both genetic data and a wide range of phenotypical measurements, which will become 
available to the wider scientific community in its entirety in the course of 2016. Similar 
large efforts are Lifelines in the Netherlands34 and the Estonian Biobank in Estonia35. In 
addition, there are more private biobanks available, such as the The Research Program 
on Genes, Environment, and Health (RPGEH), a scientific research program from health 
insurer Kaiser Permanente, that has measured health factors, genetic information from 
saliva and blood) of also 100K individuals36, but is planning to reach 500K samples37. An 
interesting source of biobank data comes from 23andMe38, a privately held personal 
genomics and biotechnology company based in California. It allows people to send their 
saliva in a testing kit to have their genomes screened for genes associated with certain 
inherited conditions, such as cystic fibrosis or sickle cell anaemia, and other genetic 
markers relating to health and ancestry. Participants can opt to make their genomes 
available (anonymised) to the scientific community, combined with data retrieved from 
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self-reported health surveys, As of 2015, 23andMe had reached the 1 million mark for 
genotyped individuals39, and given that 80% of them opt-in to participate in research40, 
this makes it one of the largest medical genetic research databases in the world.
Public availability of data
A final and rather easy way to quickly increase sample sizes or in general making the 
most of already generated data is simply done by making data publicly available41. The 
Wellcome Trust Case Control Consortium (WTCCC) study on seven common diseases42 
was one of the first that made genotype and phenotype data publicly available to other 
researchers, making the best use of often publicly funded research. Typical examples 
are the use of this data for imputation of genotypes, and recently also imputation of 
epigenomic markers43 using already generated reference epigenomic datasets, or the 
inference of eQTLs44 based only on cohort genotypes and publicly available reference 
expression data. Imputation of epigenomes is useful as trait-associated variants affect 
regulatory regions in a cell-type dependent manner45, and it is not always feasible to map 
every epigenetic mark in every tissue, cell type and condition of interest. Imputation of 
epigenomes for specific cell-types enables cell-type / tissue specific postGWAS analyses 
to understand phenotype specific regulatory consequences of variants identified in a 
GWAS. Similarly, eQTLs can be cell-type specific46,47, and appropriate cellular context 
enables a better understanding of variant consequences on expression level in relevant 
tissue.  This is exactly why platforms such as the database of Genotypes and Phenotypes 
(dbGaP)48 or the European Genome Phenome (EGA)49 archives have been set up. Even 
though for large meta-GWAS consortia, making data publicly available is difficult, if not 
impossible due to the many participating studies, all with accompanying release policies 
and other political stakes, some of these do make the final genome-wide summary 
statistics available. This allows easy combination of study statistics or replication, and can 
be done even in the case of unknown proportions of sample overlaps by methods such as 
METACARPA50, and also allows much easier and larger-scale Mendelian Randomisation-
like analyses based on GWAS summary statistics using packages like Genetics ToolboX 
(GTX)51, as used in Chapter 7. To ensure that the vast lakes of generated data are not only 
publicly available, but also are truly accessible, newer models to improve the portability 
of data are being developed.52
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9.1.2. Increase in resolution
Deep sequencing
Regardless of sample size, GWAS analyses are only able to address variants that have 
been identified and are assessable on a genotype chip, or inferred by imputation. As 
we continue to sequence many more individuals, more variation is identified, and it has 
become clear that rarer variation may explain parts of the missing heritability as well for 
certain traits53. In other words, improving genomic resolution is another feasible way to 
improve genetic discovery, as has already been demonstrated by comparing Hapmap to 
1000 Genomes imputation for various traits and the observed improvement in terms 
of additional loci discovered and fine-mapping54. Sequence efforts continue to grow 
and efforts such as the Haplotype Reference Consortium55,56, that combine sequencing 
data from multiple cohorts, provide greatly enriched imputation panels, the creation of 
which will substantially improve genetic discoveries. Similar efforts to map and collect 
human genetic variation are ongoing for non-European populations, such as the African 
Genome Variation Project57, and efforts by the Sequencing Isolates Consortium (SILC) 
that brings together a reference panel of sequenced genomes from population isolates. 
Many more sequence efforts are underway, that may uncover new variants such as the 
100,000 Genomes project by Genomics England58, but also the mind-boggling plan of 
BGI to sequence 3 million genomes59, amongst which 1 million human, complemented 
by projects that will establish deeper and more refined reference maps of the human 
genome, such as the Human Genome Variation Map60. Nevertheless, sequencing such 
a large number of individuals at reasonable costs is still prohibitive for the majority 
of GWAS efforts, where at least in the short-term we will remain in an intermediate 
phase, utilizing whole genome sequences as imputation references and not directly in 
association analyses61. 
Neglected parts of the genome
Even though many genomes have been sequenced and analysed, certain regions in the 
genome are largely neglected in genome-wide analyses, such as the Y-chromosome or 
mitochondrial chromosomes, often due to complications in genotype calling, imputation, 
and selection of test statistics, as well as a lower proportion of genes, and a lower coverage 
of current genotyping platforms compared with autosomal chromosomes62–64. There is 
ample evidence for genetic regions in these chromosomes to be involved in a wide range 
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of traits and diseases, including auto-immune diseases65–67. Investing in the large-scale 
analyses of these chromosomes, through efforts such as YGEN, the first international 
consortium that will assess the influence of Y-chromosome variation on complex traits 
of public health or evolutionary interest, are likely to provide a multitude of additional 
insights into the contribution of variants on neglected chromosomes to complex traits68. 
In a similar way, certain genetic regions have been rarely analysed due to the difficulty 
to type and impute these regions, the best known examples being the immunologically 
important complex regions such as the HLA region and killer cell immunoglobulin-like 
receptors (KIRs). Recent methods have however enabled the proper imputation of these 
regions69,70, allowing the detailed investigation of their role in human disease.
Fine-mapping
With deeper imputed data, it becomes more likely that a causal variant will be present 
in the set of analysed variants. It remains however not straightforward to identify 
these, especially given that the vast majority of associated variants fall outside coding 
regions71, whereas until very recent the majority of annotation efforts have focused on 
coding variants72. Newer developments in fine-mapping such as CADD73 and Eigen74 
have integrated extensive functional genomic annotations into a per-variant score 
of functionality, including conservation scores, epigenomic annotations and protein-
level consequence scores. This importantly enables the prioritisation of variants that 
are intergenic or in non-coding regions, where previously this was challenging. A well-
known example being the 9p21 region for CAD, the first reported CAD locus through 
GWAS, for which top-variants were intergenic, raising many questions on the biological 
nature of this association and the responsible causal variant75. Other approaches such 
as CAVIARDB76, are able to highlight the most likely causal variants in a locus, just using 
summary statistics and PICS77, provides similar fine-mapping capabilities, but then also 
includes prior knowledge such as transcriptional and epigenomic data, promising much 
improved fine-mapping results.
Capitalising on population diversity
Besides enhancing genetic discoveries by doing the obvious – increasing sample-sizes 
and analysing enriched sources of variants, one should not underestimate the value 
of population genetic diversity. Selection pressure due to environmental factors or 
187
Discussion and future perspectives
population bottlenecks may have genetic consequences, that is, genetic variants that are 
common in one population may be rare or even absent in other populations due to a 
reduced haplotype diversity, or vice versa. The genetic differences between populations 
can be exploited in various ways for genetic discovery. Firstly, as also discussed earlier, 
differences in LD structure may help to further narrow down genetic regions associated 
with a trait78, thereby more accurately pinpointing the location of actual causal variants. 
Secondly, studying different populations can improve the discovery of rare risk variants 
in loci already highlighted by common variants found by GWAS. When variants rise in 
frequency, the statistical power to detect these when they underlie the investigated trait 
will also increase. Whereas in outbred populations certain variants are too low in frequency 
to be picked up in association studies, higher frequencies of variants in relatively small and 
homogeneous populations can be identified. This has been demonstrated in, for example, 
Greek isolates,79 or the Icelandic population80. One caveat however is that differences 
in variant frequencies and LD-structure between populations implicate that associated 
variants within one population are not automatically replicable in other populations, 
hence careful replication strategies must be devised when attempting cross-population 
replication in GWAS81. 
9.1.3. Increase in throughput and moving towards ‘big data’
As discussed earlier, genetic discovery can be greatly aided by increasing sample sizes 
and high-depth sequencing, which however come at a substantial cost both financially 
and time wise, though costing much less than the sequencing of the first human genome 
at $2.7 billion in 199182 ($4.7 billion inflation adjusted), whereas now the $1000 dollar 
genome is a reality83, or, almost84. Newer developments on the horizon do offer prospects 
to lower these hurdles. One promising technique is nanopore or ‘strand sequencing85,86, 
a ‘lab on a chip’ technique that passes a single strand of intact DNA polymers through 
a protein nanopore, sequencing in real time as the DNA translocates the pore. Bases 
are identified by the way they affect ions flowing through the pore from one side of 
the membrane through the other, without the need to amplify DNA, saving expensive 
reagents. Therefore, the technique is cheaper and has also shown to be much faster87, 




Such advances, in concert with ever-increasing biobanking efforts are resulting in huge 
mountains of data for which matching raw computational power and infrastructure is 
required. Having the oncoming tidal wave of data in mind, the problem of data processing 
in genetics should be treated as any other ‘big data’ issue89. 
On the GWAS analysis front, developments like Genotype Query Tools (GQT)90, provide 
novel data indexing strategies and much improved data compression, resulting in 
substantial query analysis performance improvements over current state-of-the-
art tools of over 400 fold. In parallel, algorithms are continuously optimised, whereby 
borrowing techniques from other fields of research such as signal processing91 or artificial 
intelligence92 offer further improvements in deciphering the human genomic architecture.
On the hardware front other developments continue to contribute to ever more efficient 
genetic discovery. For example, sequencing pipelines, typically using algorithms running 
on high-end computer clusters on general CPUs, are being integrated in processors 
themselves (i.e. ‘hard-coded’). Edico Genome’s reconfigurable DRAGEN Bio-IT Processor 
has hard-coded highly optimized algorithms for the full next generation sequencing 
(NGS) secondary analysis pipeline, including mapping, aligning, sorting, compression 
and haplotype variant calling, and can be integrated directly into NGS machines and 
bioinformatics servers93. Compared to conventional sequencing pipelines, the company 
recently showed that this processor reduces the time needed to analyse a whole human 
genome, from 24 hours to 18 minutes, a speed increase of 80 fold. 
Thus, solving data processing problems in genomics requires supercomputing 
infrastructure and expertise for which industry standards should be adopted. There are 
two main bottlenecks in the classical way of data management, the first lies in the way 
files are stored and handled, the second in the way data is processed. Traditionally, files 
are stored physically on a drive. Disk size then limits the size of the files to be stored. 
Secondly, when data needs to be processed, data is conventionally moved over a network 
to be processed by software, which can be extremely slow, in particular for large data 
sets.
In industry, these problems are tackled by a powerful open source distributed platform to 
store and manage big data, called Hadoop, which tackles the aforementioned problems 
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in various ways, and holds promise for the application of big data analytics to genomics94. 
What Hadoop does differently, is that it breaks down large datasets into many small files 
(‘chunks’ or ‘blocks’), which are stored and distributed across the nodes of a computer 
cluster. Secondly, the MapReduce element of Hadoop, reads data from the database, 
then puts it into a format suitable for analysis (map), produces customised datasets with 
only the needed data (reduce), and moves the processing algorithms to the data instead 
of the other way around95. With ever increasing sizes of genomics data, approaches like 
Hadoop are already being adapted by the scientific community96,97 , simply out of sheer 
necessity.
9.2. Increase in understanding (from genotype to phenotype) 
As argued in Chapter 8, where we review and evaluate the genetic insights in coronary 
artery disease, discovery and interpretation of genetic loci influencing traits requires 
insights from multiple intermediates through which genetic loci exert their effects on 
the phenotype in order to be able to obtain causal and mechanistic insights. This means 
integrating genetic data with expression data (eQTL), regulatory elements and effectors, 
proteomes, metabolomes, and intermediate phenotypes, all of which are interacting 
biological effector levels that have their effects on the final outcome studied. Yet another 
phenotypic level to be considered is the microbiome. Apart from more intuitive associations 
of the microbiome with disease, such as inflammatory bowel disease98, there are also 
indications that it influences psychiatric99,100 and cardiovascular outcomes101, whereas 
the composition of the microbiome itself is also influenced by genetic variation of the 
host102, which brings yet another dimension to integrative genotype-phenotype analyses. 
Various efforts have been undertaken to obtain, map and interpret the aforementioned 
data types. Databases such as Genotype – Tissue Expression (GTEx)103 and Expression 
Atlas104 collect and organise gene expression data derived under different biological 
conditions and in different tissues, allowing the discovery of eQTL across different tissue 
types, and combine these sometimes tissue-specific eQTLs with network analyses such 
as done in Chapter 6. 
Similarly, large efforts have been undertaken to map epigenomic data, such as in the 
ENCODE105 and Roadmap Epigenetics Project106, Blueprint Epigenome107, but also for 
proteome (HPP)108, and even microbiome (HMP)109 data exists on a comparable large 
scale. Efforts such as HipSci110, that enable to retrieve these data simultaneously from 
190
Chapter 9
pluripotent stem cells allow insights in developmental and differentiation mechanisms 
on a cellular level, and projects such as the UK Digital Heart Project111, having digitally 
reconstituted entire human hearts from echocardiographs, may even have the potential 
to uncover genetic effects on a precise organic scale. Nevertheless, linking and integrating 
these biological data types will on the one hand undoubtedly improve our understanding 
of higher-order networks and mechanisms driving inflammatory phenotypes across 
multiple tissues, but also bring along a great challenge to build statistical models, 
although many promising methods are already available112. 
9.3. Clinical relevance and impact
Bearing the previous paragraph in mind, translation of identified genetic variation or 
loci into pathogenic molecular mechanisms appears more feasible than ever before. 
Nevertheless, the potential clinical relevance remains a key debate. In practise however, 
GWAS findings have already proven to be clinically informative in a number of ways.
9.3.1. Risk prediction 
One of the most straightforward clinical applications of GWAS findings is (genetic) risk 
prediction of disease, where individual-level risk estimates may help in early intervention 
and improve diagnostic procedures. Though various methods exist, they make use of the 
same principle: a set of variants (typically genome-wide) is tested for association with a 
phenotype, of which a subset that is positively associated is used to produce predicted 
phenotypes, typically in terms of a continuous genomic risk score (GRS). There have 
been numerous studies developing risk prediction models using genetic markers, with a 
few successful examples113,114, but mostly GWAS-informed risk prediction models have 
turned out less successful than initially anticipated113,115. One of the major reasons being 
the low effect size of SNPs for common complex diseases identified in GWAS and the 
relatively low explained variance by these. Therefore, the practical applicability of genetic 
risk scores in a clinical setting largely depends on the underlying genetic architecture of 
the disease of interest and achievable sample sizes in studies identifying genetic risk 
variants116. At least in the near future genetic risk scores will, therefore, need to be used 
as an addition to more established clinical risk factors.
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9.3.2. Causal inference and identification of novel risk factors for disease
Given that there is widespread evidence of genetic correlations between traits and 
diseases117, there is ample opportunity to investigate causality directions. Using genetic 
risk scores, it has been confirmed that LDL levels are causal to CAD118, stressing that LDL-
cholesterol lowering interventions such as adjusted diets and LDL lowering medication 
will have effects, as demonstrated also in a recent meta-analysis of randomised, 
controlled trials (RCTs)119. We ourselves investigated effects of CRP genetic risk scores 
on 32 different outcomes, and found causal effects of CRP on schizophrenia, notably a 
protective effect, and nominal effects on blood pressure. Nevertheless, causal findings 
do not necessarily readily translate to clinical value. In our case for example, it would 
not make sense to administer medication that increases CRP levels to reduce risk of 
schizophrenia, thereby increasing the body’s inflammatory state, which understandably 
is a greatly undesired effect. Secondly, schizophrenia is a highly polygenic and complex 
disease, with a plurality of other factors that may contribute to it’s development, of which 
lowered genetic levels of CRP are one out of many. In the case of our nominal finding of 
genetically elevated levels of CRP causing elevated levels of blood, administration of anti-
inflammatory medication that lowers elevated peripheral CRP may also help to lower 
blood pressure. The identification of previously unknown risk factors has therefore the 
potential to aid disease management, but this strongly depends on a number of factors, 
most importantly the genetic architecture of the disease, and available strategies for 
intervention.
9.3.3. Disease stratification
Another application comes in the form of disease classification, where for example Sirota 
and colleagues show that they were able to classify auto-immune diseases120, identifying 
SNPs that make an individual susceptible to one class of autoimmune disease whilst 
simultaneously protecting from diseases in the other autoimmune class. This may enable 
clinicians to more optimally tailor treatment, as certain drugs for example are known to 
improve one type of autoimmune disorders, whilst having negative effects on another. 
A good example for this is infliximab, which is an antibody that binds to TNF, one of the 
inflammatory markers investigated in this thesis (Chapter 3). Typically prescribed and 
working well for RA and ankylosing spondylitis (AS)121,122,  it however has no efficacy and 
sometimes even worsens the condition in individuals with other auto-immune diseases 




A major area where GWAS may play a role is in pharmacogenomics. As modern 
medication only recently appeared as an environmental factor, it will not have caused any 
negative evolutionary selection pressures on common variants associated with (severe) 
adverse drug reactions (ADRs). Successful discoveries related to inflammatory disorders 
include identification of loci for ADRs against Lumiracoxib124, a drug that is prescribed 
for the treatment of osteoarthritis and rheumatoid arthritis, causing liver injury, and loci 
associated with ADRs against thiopurin125,126, prescribed for autoimmune disorders such 
as Crohn’s disease and rheumatoid arthritis, causing leukopenia and pancreatitis.
Apart from identification of loci related to ADRs, GWAS can also aid in identifying drug 
targets127,128. By making clever use of known gene-drug target databases such as 
DrugBank129, therapeutic target database (TTD)130 and PharmGKB131,  one can overlap 
genes identified in loci in a meta-analysis, or their interacting gene products132 and filter 
out those that appear druggable for further study. As many of the compounds in these 
databases are already FDA approved, this creates a wealth of opportunities for drug 
repurposing and repositioning133, bypassing the necessary lengthy and costly process of 
clinical safety trials. Lastly, GWAS findings may assist in patient stratification, for example 
by enabling optimised treatment by tailoring doses of drugs depending on an individuals 
genetic profile, such as for asthma134. 
In all, genetic discoveries are very likely to contribute in various ways to the realisation of 
personalised medicine135, whereby personal (inflammatory) biomarker-specific profiles 
affected by genetic, clinical and lifestyle factors are likely to play an important role136. 
9.4. Consequences for the general public of advances in genetic discovery
With the promise of personalised medicine, the generation of data lakes, availability of 
electronic health records (EHRs) for genomic research137 and these being made available 
to many scientists, all of which presenting sensitive information regarding individual 
genomic and health profiles, privacy becomes a key concern. Even though most research 
bodies have stringent policies regarding anonymisation of data, implemented in law such 
as the Data Protection Act in the UK138, if one has access to an individual’s DNA, it is rather 
straightforward to identify presence of these individuals in databases139. Just 5000 SNPs 
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are needed in databases of 1000 individuals and the number of SNPs needed declines 
with the number of samples in a database, even in the presence of sequencing errors and 
variant-calling differences140.
Advances in genotyping, making it cheaper and more accessible through efforts such as 
23andMe or more widespread use in clinical practice, simultaneously generated interest 
in the use of genetic information for purposes other than medical research. For example, 
when linked to electronic health records this information is valuable for insurance or 
employment purposes, as genetic tests can be used to detect inherited conditions that 
may have a financial impact. This generates concerns regarding for example employment 
decisions, possibly the invocation of charging higher insurance premiums or even denial 
of coverage141, fears that are most certainly not unreasonable142–144. 
These fears can have various consequences, the most important being individuals that 
avoid genetic testing, thereby firstly missing out on health benefits these tests can 
provide, and secondly resulting in negative views on research in medical genomics with 
all sorts of consequences such as decreased study participation (not giving consent), or 
even a reduction in funding. 
To enable further advances in medical genomic research, it remains therefore pivotal for 
scientists to properly inform the public about advances and concepts in genomics in an 
accessible manner, in particular when giving consent to using genetic and phenotypic 
information in medical genetic studies, and secondly to guarantee absolute anonymity 
by implementing stringent data management policies145. Simultaneously, governments 
should adhere to extremely strict rules regarding the use of genetic testing, such as in 
the Netherlands, where the Medical Examination Act greatly restricts the use of genetic 
information of clients by insurance companies146.
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9.5. Final conclusions and recommendations 
To make the most of advances in genetic discovery, I propose the following: 
1. Boosting the public availability of scientific output
Firstly, scientific research should be made publicly available whenever possible, especially 
given the fact that a lot of medical genetic research is more often than not publicly 
funded. Simultaneously, publication in open access journals should be encouraged. This 
would have various important benefits, some of the most important being the proper 
return of investment to the general public, generating the possibility for institutes in 
countries with challenging economic environments to stay on par with those in more 
prosperous societies, and last but not least making the most of costly data by recycling 
these for other experiments. In particular the non-public access to scientific journals, 
(i.e. these are behind a ‘pay-wall’) has aggravated many a researcher, so much so that 
this has culminated in what is known as the ‘Pirate Bay’ for scientists (http:/sci-hub.cc), 
where 47 million scientific papers are publicly available that otherwise would be behind 
a pay-wall147. Without publicly available data, the majority of work in this thesis would 
not have been possible, be it the GWAS analyses in Chapters 2 to 5 using Hapmap based 
data, Chapters 6 using publicly available functional databases, and Chapter 7, in press in 
an open-access journal (PLOS Medicine) at the time of writing, and using mostly publicly 
available GWAS summary statistics. Several initiatives are already in place to more or less 
‘force’ scientists, to make data publicly available148–150, though this is currently more of an 
exception than a rule.
2. Investment in method development using publicly available data
There should be an even greater extent of method development, to make better use 
of publicly available summary statistics. Various methods and applications have been 
mentioned earlier, but some straightforward and widely applicable methods in the 
context of GWAS meta-analysis are DISTMIX151 and ImpG152. Both are applications that 
allow the extension of GWAS summary statistics to variants from deeper imputation 
references using just summary statistics of a GWAS meta-analysis output file without the 
need of actual re-imputation of individual cohorts to the imputation reference. This firstly 
greatly reduces computational burden, and secondly can enhance evidence of functional 
enrichment due to a higher resolution. The re-use of publicly available summary statistics 
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is both financially and time-wise very advantageous in replication studies. A recently 
developed meta-analysis implementation named METACARPA* allows meta-analysis of 
summary statistics from public data with one’s own study without having to worry about 
overlap, an initially big hurdle to use publicly available summary statistics for replication. 
3. Fostering collaborations between business and science
Thirdly, to fulfil the promise of personalised (genetic) medicine, collaboration between 
academia and industry is essential153, and is known to have many other advantages154, and 
therefore must be fostered. This does however require improved models of collaboration 
in order to succeed, overcoming issues such as a mutual lack of trust regarding intellectual 
property, uncertainty about the potential benefits of working together and outputs from 
collaborations that are worthwhile for both universities and businesses155.
4. Adaptation of industrial big data standards
For reasons mentioned earlier in the discussion, (academic) and non-profit medical 
research entities should aim to adapt industry standards when it comes to big data 
analysis and management.
5. Giving back to the public
Given the public interest and funding of vast parts of on-going medical genetic research, 
efforts to communicate with the general public about scientific findings and concepts 
should be heavily invested in, thereby aiming to create public trust, not the least through 
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